Peter A. Anton

Senior Faculty & Chief Medical Officer – Biomedicine

B.A., 1977, Harvard University, Biology

Institute of Pathology Fellowship, 1981, University Hospitals, Case Western Reserve University Medical School, Cleveland, OH

M.D., 1983, Case Western Reserve University Medical School, Cleveland, OH

Residency, 1986, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA

Fellowship (Gastroenterology), 1989,  UCLA GI Training Program, David Geffen School of Medicine at UCLA

Assistant-Full Professor of Medicine UCLA: 1989-2015

Professor of Medicine UCLA: 2015-present

Senior Faculty & Chief Medical Officer, Oak Crest: Sep., 2017-present

Principal Research Interests

  • Characterization of normative and altered mucosal immune responses of the gastrointestinal (GI)-associated lymphoid tissue (GALT) in the healthy and diseased human GI tract, e.g., in inflammatory bowel diseases (IBD), infectious diseases such as HIV infection
  • Facilitate translational testing in humans (observational studies, exploratory & Phase 1 trials)
  • Novel biomedical systems for preventing (topical/implant/vaccine) and treating/functional cure: HIV and other infectious diseases
  • Characterization and targeted delivery of probiotic systems for combating infectious diseases
  • Clinical Pharmacology of drugs and other biotherapies in targeted compartments/tissues
  • Mentoring the next generation of scientists

Representative Publications

  • Fulcher, J.A., Koukos, G., Koutsioumpa, M., Elliott, J., Drakaki, A., Iliopoulos, D., Anton, P.A. (2017). Unique microRNA expression in the colonic mucosa during chronic HIV-1 infection. AIDS, 10;31(14):1925-34. PMCID:PMC5578872.
  • Leyva, F., Fuchs, E.J., Bakshi, R., Carballo-Dieguez, A., Ventuneac, A., Yue, C., Caffo, B., Du, Y., Torbenson, M., Li, L., Mullen, G., Lee, L., Rohan, L., Anton, P., Hendrix, C.W. (2015) Simultaneous evaluation of safety, acceptability, peri-coital kinetics, and ex vivo pharmacodynamics comparing four rectal microbicide vehicle candidates. AIDS Res Hum Retroviruses, 31(11):1089-97. PMCID: PMC4651043.
  • McGowan I, Cranston RD, Duffill K, Siegel A, Engstrom JC, Nikiforov A, Jacobson C, Rehman KK, Elliott J, Khanukhova E, Abebe K, Mauck C, Spiegel HM, Dezzutti CS, Rohan LC, Marzinke MA, Hiruy H, Hendrix CW, Richardson-Harman N, Anton PA. A phase 1 randomized, open label, rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of three formulations of Tenofovir 1% gel (the CHARM-01 Study). PLoS One2015;10(5):e0125363.
  • Preza, G.C., Tanner, K., Elliott, Yang, O.O., Anton, P.A., Ochoa, M-T. Antigen presenting cell candidates for HIV-1 transmission in human distal colonic mucosa defined by CD207 Dendritic Cells and CD209 macrophages. AID Research & Human Retroviruses 2014; 30(3):241-249.
  • Yang, O.O., Ibarrondo, F.J., Price, C., Hultin, L.E., Elliott, J., Hultin, P.M.; Shih, R.; Hausner, M.A.; Hwee, L.N., Hoffman, J., Jamieson, B.D., Anton, P.A. (2014) Differential blood and mucosal immune responses against an HIV-1 vaccine administered via inguinal or deltoid injection. PLOS One, 9(2):e88621. PMCID: PMC3928250.
  • McHardy IH, Li X, Tong M, Ruegger P, Jacobs J, Borneman J, Anton P, Braun J. (2013). HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome, 1(1) 26. PMCID: PMC3971626.
  • Anton PA, Cranston RD, Kashuba A, Hendrix C, Bumpus NN, Richardson-Harman N, Elliott J, Janocko L, Khanukhova E, Dennis RA, Cumberland WG, Ju C, Carballo-Dieguez A, Mauck C, McGowan IM. (2012). RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Compared to Oral Tenofovir Disoproxil Fumarate. AIDS Res Hum Retroviruses, 28(11) 1412-1421. PMCID: PMC3484811.
  • Richardson-Harman N, Mauck C, McGowan I, Anton P. (2012). Dose response relationship between tissue concentrations of UC781 and explant infectibility with HIV-1 in the RMP-01 rectal safety study. AIDS Res Hum Retroviruses, 28(11) 1422-1433. PMCID: PMC3484735.
  • Anton, P.A., Saunders, T., Elliott, J., Khanukhova, E., Dennis, R., Adler, A., Cortina, G., Tanner, K., Boscardin, J., Cumberland, W., Zhou, Y., Ventuneac, A., Carballo-Diéguez, A., Rabe, L., McCormick, T., Gabelnick, H., Mauck, C., McGowan, I. First Phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy, PLOS ONE, 6:9:e23243, 2011.
  • Anton PA, Ibarrondo FJ, Boscardin WJ, Zhou Y, Schwartz EJ, Ng HL, Hausner MA, Shih R, Elliott J, Hultin PM, Hultin LE, Price C, Fuerst M, Adler A, Wong JT, Yang OO, Jamieson BD. (2008). Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments. Vaccine, 26(35) 4617-4623. PMCID: PMC2570228.
  • Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, Shattock RJ, McGowan I, Margolis L, Anton P. (2007). HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with. AIDS, 21(10) 1263-1272.
  • McGowan I, Elliott J, Cortina G, Tanner K, Siboliban C, Adler A, Cho D, Boscardin WJ, Soto-Torres L, Anton PA. (2007). Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr, 46(4) 417-425.
  • Fletcher, P.S., Elliott, J., Grivel, J-C., Margolis, L.B., Anton, P., McGowan, I., Shattock, R.J. Ex-vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS, 20;1237-1245, 2006.
  • Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MMP, McGowan I, Brown S, Anton PA. (2006). Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. JAIDS, 43(1) 65-68.
  • Gurney, K.B., Elliott, J., Nassanian, H., Song, C., Soilleux, E., McGowan, I., Anton, P.A., Lee, B. Binding and transfer of Human Immunodeficiency Virus by DC-SIGN+ cells in human rectal mucosa. J Virol, 79;5762-5773, 2005.
  • Ibarrondo FJ, Anton PA, Fuerst M, Ng HL, Wong JT, Matud J, Elliott J, Shih R, Hausner MA, Price C, Hultin LE, Hultin PM, Jamieson BD, Yang OO. (2005). Parallel Human Immunodeficiency Virus Type 1-Specific CD8+ T-Lymphocyte Responses in Blood and Mucosa during Chronic Infection. J Virol, 79(7) 4289-4297.
  • McGowan I, Elliott J, Fuerst M, Taing P, Boscardin J, Poles M, Anton P. (2004). Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation. J Acquir Immune Defic Syndr, 37(2) 1228-1236.
  • Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, Macken C, Richman DD, Christopherson C, Borellini F, Lazar R, Hege KM. (2003). Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS, 17(1) 53-63.
  • Shacklett BL, Yang O, Hausner MA, Elliott J, Hultin L, Price C, Fuerst M, Matud J, Hultin P, Cox C, Ibarrondo J, Wong JT, Nixon DF, Anton PA, Jamieson BD. (2003). Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods, 279(1-2) 17-31.
  • Anton PA, Poles MA, Elliott J, Mao SH, McGowan I, Lenz HJ, Chen IS. (2001). Sensitive and reproducible quantitation of mucosal HIV-1 RNA and DNA viral burden in patients with detectable and undetectable plasma viral HIV-1 RNA using endoscopic biopsies. J Virol Methods, 95(1-2) 65-79.
  • Anton, P.A., Elliott, J., Poles, M.A., McGowan, I.M., Matud, J., Hultin, L.E., Grovit-Ferbas, K., Mackay, C.R., Chen, I.S.Y., Giorgi, J.V.  Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue.  AIDS 14:1761-1765, 2000.
  • Olsson, J., Poles, M., Spetz, A-L., Elliott, J., Hultin, L., Giorgi, J., Andersson, J., Anton, P.A. Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and β-chemokines. J. Infect. Dis. 182:1625-1635, 2000.
  • Million, M., Taché, Y., Anton, P.A.  Susceptibility of Lewis and Fischer rats to stress-induced worsening of TNB-colitis: protective role of brain CRF.  Am. J. Physiol.  276:G1027-G1036, 1999.
  • McGowan, I., Fairhurst, R.M., Shanahan, F., Anton, P.A. Mucosal substance P receptor expression in HIV infection and inflammatory bowel disease. Neuroimmunomodulation, 4:70-76, 1997.
  • Anton, P.A., Kemp, J.A., Butler, T., Jacobs, M.R. Comprehensive efficacies of ceftriaxone, moxalactam and ampicillin in experimental Salmonella typhimurium infection. Antimicrob. Agents Chemother. 22:312-315, 1982.
  • Jacobs, M.R., Tomashefski, J.F., Franco, A., Anton, P.A. Penicillin susceptibility testing of gonococci by disc diffusion. J. Antimicrob. Chemother. 7:319-330, 1981.
  • Ng, W.S., Anton, P.A., Arnold, K. Neisseria gonorrhea strains isolated in Hong Kong: In vitro susceptibility to 13 antibiotics. Antimicrob. Agents Chemother. 19:12-17, 1981.